| Name | Title | Contact Details |
|---|
Gallagher Medical Products is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
C. R. Bard is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialties. Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. Bard pioneered the development of single-patient-use medical products for hospital procedures; today Bard is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall health care costs.
PureFlora was founded in 2012 by Tivon Sidorsky, MD after a family member’s severe case of C. difficile introduced him to the efficacy of fecal matter transplants (FMT) and the need for a standardized, sanitary, and labor reducing system by which to collect, process, and deliver fecal matter. Recognizing the tremendous opportunity for research and clinical applications for human gut microbiota and the elegant solution proposed by Dr. Sidorsky, veteran medical device executive William L. Mince joined forces with the inventor building the now-patented technology and team that is PureFlora.
Lucira Health has developed an at home COVID-19 test kit that delivers PCR quality molecular accuracy in the palm of your hand in 30 minutes or less. Our technology is transforming how we reduce the spread of infectious diseases by bringing accurate, easy-to-use self-testing into the home. This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
We are a medical technology company developing next-generation solutions for the treatment of chronic venous insufficiency, a progressive medical condition affecting an estimated 10% of adults.